143 related articles for article (PubMed ID: 34875111)
1. An observational study of intermediate- or high-dose thromboprophylaxis for critically ill COVID-19 patients.
Jonmarker S; Litorell J; Dahlberg M; Stackelberg O; Everhov ÅH; Söderberg M; Rubenson-Wahlin R; Günther M; Mårtensson J; Hollenberg J; Joelsson-Alm E; Cronhjort M
Acta Anaesthesiol Scand; 2022 Mar; 66(3):365-374. PubMed ID: 34875111
[TBL] [Abstract][Full Text] [Related]
2. Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients.
Jonmarker S; Hollenberg J; Dahlberg M; Stackelberg O; Litorell J; Everhov ÅH; Järnbert-Pettersson H; Söderberg M; Grip J; Schandl A; Günther M; Cronhjort M
Crit Care; 2020 Nov; 24(1):653. PubMed ID: 33225952
[TBL] [Abstract][Full Text] [Related]
3. Safety profile of enhanced thromboprophylaxis strategies for critically ill COVID-19 patients during the first wave of the pandemic: observational report from 28 European intensive care units.
Lavinio A; Ercole A; Battaglini D; Magnoni S; Badenes R; Taccone FS; Helbok R; Thomas W; Pelosi P; Robba C;
Crit Care; 2021 Apr; 25(1):155. PubMed ID: 33888132
[TBL] [Abstract][Full Text] [Related]
4. The impact of protocol-based high-intensity pharmacological thromboprophylaxis on thrombotic events in critically ill COVID-19 patients.
Atallah B; Sadik ZG; Salem N; El Nekidy WS; Almahmeed W; Park WM; Cherfan A; Hamed F; Mallat J
Anaesthesia; 2021 Mar; 76(3):327-335. PubMed ID: 33047335
[TBL] [Abstract][Full Text] [Related]
5. Failure of anticoagulant thromboprophylaxis: risk factors in medical-surgical critically ill patients*.
Lim W; Meade M; Lauzier F; Zarychanski R; Mehta S; Lamontagne F; Dodek P; McIntyre L; Hall R; Heels-Ansdell D; Fowler R; Pai M; Guyatt G; Crowther MA; Warkentin TE; Devereaux PJ; Walter SD; Muscedere J; Herridge M; Turgeon AF; Geerts W; Finfer S; Jacka M; Berwanger O; Ostermann M; Qushmaq I; Friedrich JO; Cook DJ;
Crit Care Med; 2015 Feb; 43(2):401-10. PubMed ID: 25474533
[TBL] [Abstract][Full Text] [Related]
6. In-hospital survival of critically ill COVID-19 patients treated with glucocorticoids: a multicenter real-world data study.
Angermair S; Hardenberg JH; Rubarth K; Balzer F; Akbari N; Menk M; Spies C; Eckardt KU; Poddubnyy D; Siegmund B; Schneider T; Treskatsch S
Sci Rep; 2024 May; 14(1):12138. PubMed ID: 38802435
[TBL] [Abstract][Full Text] [Related]
7. Thromboprophylaxis in Hospitalized Non-Critically Ill Patients With Mild-to-Moderate COVID-19 Infection: A Systematic Review and Meta-Analysis.
Hafiz A; Alkofide H; Al Sulaiman K; Joharji H; Aljohani S; Sarkhi KA; Alharbi R; Korayem GB; AlFaifi M; Alsohimi S; Aljuhani O
Clin Appl Thromb Hemost; 2023; 29():10760296231191123. PubMed ID: 37547931
[TBL] [Abstract][Full Text] [Related]
8. Venous thromboembolism and bleeding in critically ill COVID-19 patients treated with higher than standard low molecular weight heparin doses and aspirin: A call to action.
Pavoni V; Gianesello L; Pazzi M; Stera C; Meconi T; Frigieri FC
Thromb Res; 2020 Dec; 196():313-317. PubMed ID: 32977129
[TBL] [Abstract][Full Text] [Related]
9. Standard- versus intermediate-dose enoxaparin for anti-factor Xa guided thromboprophylaxis in critically ill patients with COVID-19.
Hamilton DO; Main-Ian A; Tebbutt J; Thrasher M; Waite A; Welters I
Thromb J; 2021 Nov; 19(1):87. PubMed ID: 34781984
[TBL] [Abstract][Full Text] [Related]
10. Bleeding risk by intensity of anticoagulation in critically ill patients with COVID-19: A retrospective cohort study.
Halaby R; Cuker A; Yui J; Matthews A; Ishaaya E; Traxler E; Domenico C; Cooper T; Tierney A; Niami P; van der Rijst N; Adusumalli S; Gutsche J; Giri J; Pugliese S; Hecht TEH; Pishko AM
J Thromb Haemost; 2021 Jun; 19(6):1533-1545. PubMed ID: 33774903
[TBL] [Abstract][Full Text] [Related]
11. Unchanged Characteristics and Survival among Critically Ill COVID-19 Patients during First, Second, and Third Waves: A Prospective Observational Cohort.
Ferré A; Lamamri M; Delord M; Abi-Abdallah G; Gros A; Lacave G; Laurent V; Marquion F; Merceron S; Paul M; Troché G; Convers-Domart R; Marque-Juillet S; Legriel S; Bruneel F;
Respiration; 2023; 102(6):426-438. PubMed ID: 37231952
[TBL] [Abstract][Full Text] [Related]
12. Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL.
Antic D; Milic N; Chatzikonstantinou T; Scarfò L; Otasevic V; Rajovic N; Allsup D; Alonso Cabrero A; Andres M; Baile Gonzales M; Capasso A; Collado R; Cordoba R; Cuéllar-García C; Correa JG; De Paoli L; De Paolis MR; Del Poeta G; Dimou M; Doubek M; Efstathopoulou M; El-Ashwah S; Enrico A; Espinet B; Farina L; Ferrari A; Foglietta M; Lopez-Garcia A; García-Marco JA; García-Serra R; Gentile M; Gimeno E; da Silva MG; Gutwein O; Hakobyan YK; Herishanu Y; Hernández-Rivas JÁ; Herold T; Itchaki G; Jaksic O; Janssens A; Kalashnikova OB; Kalicińska E; Kater AP; Kersting S; Koren-Michowitz M; Labrador J; Lad D; Laurenti L; Fresa A; Levin MD; Mayor Bastida C; Malerba L; Marasca R; Marchetti M; Marquet J; Mihaljevic B; Milosevic I; Mirás F; Morawska M; Motta M; Munir T; Murru R; Nunes R; Olivieri J; Pavlovsky MA; Piskunova I; Popov VM; Quaglia FM; Quaresmini G; Reda G; Rigolin GM; Shrestha A; Šimkovič M; Smirnova S; Špaček M; Sportoletti P; Stanca O; Stavroyianni N; Te Raa D; Tomic K; Tonino S; Trentin L; Van Der Spek E; van Gelder M; Varettoni M; Visentin A; Vitale C; Vukovic V; Wasik-Szczepanek E; Wróbel T; Segundo LYS; Yassin M; Coscia M; Rambaldi A; Montserrat E; Foà R; Cuneo A; Carrier M; Ghia P; Stamatopoulos K
J Hematol Oncol; 2022 Aug; 15(1):116. PubMed ID: 36028857
[TBL] [Abstract][Full Text] [Related]
13. Anti-Xa Directed Thromboprophylaxis in Critically Ill Patients with Coronavirus Disease 2019.
Mohamed A; Shemanski SM; Saad MO; Ploetz J; Haines MM; Schlachter AB; Hamarshi MS
Clin Appl Thromb Hemost; 2022; 28():10760296221116350. PubMed ID: 35924413
[No Abstract] [Full Text] [Related]
14. Venous Thromboembolism Prophylaxis: A Narrative Review With a Focus on the High-Risk Critically Ill Patient.
Lewis TC; Cortes J; Altshuler D; Papadopoulos J
J Intensive Care Med; 2019; 34(11-12):877-888. PubMed ID: 30165770
[TBL] [Abstract][Full Text] [Related]
15. Low rates of venous thromboembolism in hospitalised COVID-19 patients: an Australian experience.
Ong J; Walker P; Singh KP; Bishop E; Htun K
Intern Med J; 2022 Jan; 52(1):37-41. PubMed ID: 34524710
[TBL] [Abstract][Full Text] [Related]
16. Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy.
Grasselli G; Greco M; Zanella A; Albano G; Antonelli M; Bellani G; Bonanomi E; Cabrini L; Carlesso E; Castelli G; Cattaneo S; Cereda D; Colombo S; Coluccello A; Crescini G; Forastieri Molinari A; Foti G; Fumagalli R; Iotti GA; Langer T; Latronico N; Lorini FL; Mojoli F; Natalini G; Pessina CM; Ranieri VM; Rech R; Scudeller L; Rosano A; Storti E; Thompson BT; Tirani M; Villani PG; Pesenti A; Cecconi M;
JAMA Intern Med; 2020 Oct; 180(10):1345-1355. PubMed ID: 32667669
[TBL] [Abstract][Full Text] [Related]
17. Thromboembolic and bleeding events in ICU patients with COVID-19: A nationwide, observational study.
Russell L; Weihe S; Madsen EK; Hvas CL; Leistner JW; Michelsen J; Brøchner AC; Bastiansen A; Nielsen FM; Meier N; Andreasen AS; Ribergaard NE; Rasmussen BS; Sølling CG; Buck DL; Bundgaard H; Pedersen HS; Darfelt IS; Poulsen LM; Ibsen M; Plovsing RR; Sigurdsson ST; Iversen S; Hildebrandt T; Mohr T; Espelund US; Jørgensen V; Haase N; Perner A
Acta Anaesthesiol Scand; 2023 Jan; 67(1):76-85. PubMed ID: 36263897
[TBL] [Abstract][Full Text] [Related]
18. Prophylactic versus therapeutic dose anticoagulation effects on survival among critically ill patients with COVID-19.
Hoogenboom WS; Lu JQ; Musheyev B; Borg L; Janowicz R; Pamlayne S; Hou W; Duong TQ
PLoS One; 2022; 17(1):e0262811. PubMed ID: 35045130
[TBL] [Abstract][Full Text] [Related]
19. Incidence and mortality due to thromboembolic events during the COVID-19 pandemic: Multi-sourced population-based health records cohort study.
Aktaa S; Wu J; Nadarajah R; Rashid M; de Belder M; Deanfield J; Mamas MA; Gale CP
Thromb Res; 2021 Jun; 202():17-23. PubMed ID: 33711754
[TBL] [Abstract][Full Text] [Related]
20. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial.
; Sadeghipour P; Talasaz AH; Rashidi F; Sharif-Kashani B; Beigmohammadi MT; Farrokhpour M; Sezavar SH; Payandemehr P; Dabbagh A; Moghadam KG; Jamalkhani S; Khalili H; Yadollahzadeh M; Riahi T; Rezaeifar P; Tahamtan O; Matin S; Abedini A; Lookzadeh S; Rahmani H; Zoghi E; Mohammadi K; Sadeghipour P; Abri H; Tabrizi S; Mousavian SM; Shahmirzaei S; Bakhshandeh H; Amin A; Rafiee F; Baghizadeh E; Mohebbi B; Parhizgar SE; Aliannejad R; Eslami V; Kashefizadeh A; Kakavand H; Hosseini SH; Shafaghi S; Ghazi SF; Najafi A; Jimenez D; Gupta A; Madhavan MV; Sethi SS; Parikh SA; Monreal M; Hadavand N; Hajighasemi A; Maleki M; Sadeghian S; Piazza G; Kirtane AJ; Van Tassell BW; Dobesh PP; Stone GW; Lip GYH; Krumholz HM; Goldhaber SZ; Bikdeli B
JAMA; 2021 Apr; 325(16):1620-1630. PubMed ID: 33734299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
